Related references
Note: Only part of the references are listed.Diagnostic principles of thyroid tumors in pathology Relevant changes due to the current WHO classification
Sarah Theurer et al.
PATHOLOGE (2021)
Do Molecular Profiles of Primary Versus Metastatic Radioiodine Refractory Differentiated Thyroid Cancer Differ?
Cristiane J. Gomes-Lima et al.
FRONTIERS IN ENDOCRINOLOGY (2021)
Pan-genomic characterization of high-risk pediatric papillary thyroid carcinoma
Adam Stenman et al.
ENDOCRINE-RELATED CANCER (2021)
Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations
Alan L. Ho et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
The ETS Inhibitor YK-4-279 Suppresses Thyroid Cancer Progression Independent of TERT Promoter Mutations
Junyu Xue et al.
FRONTIERS IN ONCOLOGY (2021)
NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake
Young Ah Lee et al.
JOURNAL OF CLINICAL INVESTIGATION (2021)
Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data
Daniel A. Hescheler et al.
GASTRIC CANCER (2020)
Whole-Exome Sequencing of Matched Primary and Metastatic Papillary Thyroid Cancer
Tariq Masoodi et al.
THYROID (2020)
Intratumoral Genetic Heterogeneity in Papillary Thyroid Cancer: Occurrence and Clinical Significance
Laura Fugazzola et al.
CANCERS (2020)
Association of the Preoperative Inflammation-Based Scores with TNM Stage and Recurrence in Patients with Papillary Thyroid Carcinoma: A Retrospective, Multicenter Analysis
Wenjie Chen et al.
CANCER MANAGEMENT AND RESEARCH (2020)
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
Charles Pottier et al.
CANCERS (2020)
Combinatorial Therapies in Thyroid Cancer: An Overview of Preclinical and Clinical Progresses
Gheysen Laetitia et al.
CELLS (2020)
Novel Targeted Therapies for Metastatic Thyroid Cancer-A Comprehensive Review
Mohammad Al-Jundi et al.
CANCERS (2020)
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
L. J. Wirth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Clinical, Pathological, and Molecular Characteristics Correlating to the Occurrence of Radioiodine Refractory Differentiated Thyroid Carcinoma: A Systematic Review and Meta-Analysis
Yi Luo et al.
FRONTIERS IN ONCOLOGY (2020)
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial
Jordi Rodon et al.
NATURE MEDICINE (2019)
New treatment options in hairy cell leukemia with focus on BRAF inhibitors
Brunangelo Falini et al.
HEMATOLOGICAL ONCOLOGY (2019)
FDG PET/CT for the early prediction of RAI therapy response in patients with metastatic differentiated thyroid carcinoma
Seo Young Kang et al.
PLOS ONE (2019)
Clinical, Pathological, and Molecular Profiling of Radioactive Iodine Refractory Differentiated Thyroid Cancer
Leila Shobab et al.
THYROID (2019)
Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond
Maria E. Cabanillas et al.
ENDOCRINE REVIEWS (2019)
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
S. Kopetz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol
Amir Iravani et al.
THYROID (2019)
2019 European Thyroid Association Guidelines for the Treatment and Follow-Up of Advanced Radioiodine-Refractory Thyroid Cancer
Laura Fugazzola et al.
EUROPEAN THYROID JOURNAL (2019)
Prolonged Response to Regorafenib in a Patient with Iodine Refractory Thyroid Cancer
Selina K. Wong et al.
CASE REPORTS IN ONCOLOGY (2019)
DrugBank 5.0: a major update to the DrugBank database for 2018
David S. Wishart et al.
NUCLEIC ACIDS RESEARCH (2018)
Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
Theodore W. Laetsch et al.
LANCET ONCOLOGY (2018)
Novel targeted therapies and immunotherapy for advanced thyroid cancers
George E. Naoum et al.
MOLECULAR CANCER (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
EGFR inhibition enhances the antitumor efficacy of a selective BRAF V600E inhibitor in thyroid cancer cell lines
Yongsheng Jia et al.
ONCOLOGY LETTERS (2018)
69OLarotrectinib efficacy and safety in TRK fusion cancer: An expanded clinical dataset showing consistency in an age and tumor agnostic approach
D S W Tan et al.
ANNALS OF ONCOLOGY (2018)
Clinical safety and activity from a phase 1 study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions
D. S. Hong et al.
EUROPEAN JOURNAL OF CANCER (2017)
TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease
Miguel Melo et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2017)
CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer
Malachi Griffith et al.
NATURE GENETICS (2017)
Combination of galectin-3, CK19 and HBME-1 immunostaining improves the diagnosis of thyroid cancer
Vanessa Arcolia et al.
ONCOLOGY LETTERS (2017)
Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
Tiziana Notarangelo et al.
CANCER CELL INTERNATIONAL (2017)
Results of randomized phase II trial of dabrafenib versus dabrafenib plus trametinib in BRAF-mutated papillary thyroid carcinoma.
Manisha H. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States
Manju L. Prasad et al.
CANCER (2016)
Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial
Marcia S. Brose et al.
LANCET ONCOLOGY (2016)
DoCM: a database of curated mutations in cancer
Benjamin J. Ainscough et al.
NATURE METHODS (2016)
Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer
Seo Young Sohn et al.
THYROID (2016)
Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives
Ricardo Costa et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2016)
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia
E. Tiacci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
Martin Schlumberger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
BRAF Inhibitor Dabrafenib in Patients with Metastatic BRAF-Mutant Thyroid Cancer
Gerald S. Falchook et al.
THYROID (2015)
Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib
S. Michael Rothenberg et al.
CLINICAL CANCER RESEARCH (2015)
Integrated Genomic Characterization of Papillary Thyroid Carcinoma
Nishant Agrawal et al.
CELL (2014)
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
Marcia S. Brose et al.
LANCET (2014)
Clinical Outcomes and Molecular Profile of Differentiated Thyroid Cancers With Radioiodine-Avid Distant Metastases
M. M. Sabra et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
Sorafenib in metastatic thyroid cancer
Jaume Capdevila et al.
ENDOCRINE-RELATED CANCER (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers
Craig H. Mermel et al.
GENOME BIOLOGY (2011)
Share Paper
